iBASIS Partners with SIPPIO to Meet Fast-Growing Demand for Unified Cloud Communications
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, announced it will partner with SIPPIO, the largest, secure, Azure-based provider of voice-calling services for Microsoft Teams, globally. The relationship enables both companies to address the fast-growing global demand for unified communications and collaboration services with Cloud Numbering and International Voice Termination.
The seismic shift to all cloud-based communication platforms is exemplified by Microsoft Teams’ 145 million daily active users. As recently reported by Synergy Group Research, “Microsoft has become the second-largest Unified Communications-as-a-Service (UCaaS) provider in the world.” As usage increases, so does the demand for exponentially growing voice calling services.
iBASIS and SIPPIO are responding to this demand with iBASIS’ expansion of Cloud Numbering and International Voice Termination combined with SIPPIO’s fully automated, end-to-end cloud solution platform, delivering top-grade communications and carrier services and leveraging automation to eliminate the cost, complexity, and time of building direct routing as a ‘one-off.’ This ensures both reliability and redundancy on a global scale with the highest levels of security, compliance, and data privacy.
iBASIS provides SIPPIO with enhanced coverage in various hard-to-reach destinations across the globe. Recent examples of iBASIS’ strengths in addressing demand from key geographies include iBASIS’ partnership with China Telecom Europe, which enabled CTE to achieve instant traction by leveraging iBASIS Carrier Voice for Teamwork™ to provide European multinationals with full calling capabilities to their collaboration platforms.
“SIPPIO is an innovative cloud solution player forging new capabilities and commercialization opportunities for fully automated, cloud-based direct routing as a service,” says Edwin van Ierland, Chief Commercial Officer and Chief Operating Officer at iBASIS. “This relationship showcases how iBASIS’ Carrier Cloud Communications portfolio, global reach, scale, and independence are critical to the global requirements for cloud communications.”
“This is a pivotal moment in which the demand to shift voice calling to the same world as online meetings is a major market driver,” adds Dawn-Marie Elder, COO, SIPPIO. “Partnering with iBASIS extends SIPPIO’s global footprint, reinforcing our ability to provide operators with the highest quality, tier-1 voice capabilities and fastest time to market to bring these solutions to their enterprise customers.”
iBASIS Carrier Voice for Teamwork is part of iBASIS’ larger Carrier Cloud Communications portfolio that includes cloud numbering solutions, international numbers, global voice termination, and Communications Platform as a Service (CPaaS). iBASIS’ carrier-grade API marketplace includes a full CPaaS suite to meet the growing and urgent need for collaborative tools and applications – including solutions for iBASIS Carrier Voice for Teamwork™, two-factor authentication, live support, and contact center services.
SIPPIO empowers channel partners and carriers with capabilities to capitalize on the demand for voice-enabled collaboration platforms like Microsoft Teams. By minimizing resource consumption from end to end, SIPPIO expands the universe of potential customers for partners, making it economically viable to pursue smaller companies as well as Fortune 500 enterprises.
About iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, Top 3 LTE IPX vendor with 700+ LTE destinations, and a leading Carrier Cloud Communications player. iBASIS today serves 1,000+ customers across 18 offices worldwide. For more information, please visit iBASIS.com.
About SIPPIO
Headquartered in Annapolis, MD, SIPPIO is the largest platform provider to enable voice in Microsoft Teams. As a Co-Sell Preferred partner, SIPPIO provides partners and carriers with a fully automated, Azure native, end-to-end solution. Available globally with toll-free and emergency services, SIPPIO does not require any code, build, or maintenance. SIPPIO activates full calling capabilities in minutes and scales with business needs to enhance communications and collaboration to unify the modern workplace experience. Visit www.sippio.io for additional information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005768/en/
Contact information
iBASIS Media
Melissa Coffman
26FIVE
mc@26Five.com
202-251-1793
SIPPIO Media
Mostafa Razzak
JMRConnect
m.razzak@jmrconnect.net
202.904.2048
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom